About US
Contact us
-
Merck looks past Sanofi's dengue woes in development deal with Brazilian vaccine instituteEven after Sanofi suffered a costly dengue vaccine controversy last year, fellow pharma giant Merck & Co. isn’t backing away from the field. Instead, it hasstrucka new partnership with Brazil’s Bu2018/12/17
-
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trialAstraZeneca felt the blow last month whenMystic, a key trial examining its immuno-oncology drug Imfinzi in previously untreated lung cancer, failed. But now that the dust has settled, the company is l2018/12/17
-
Lilly teams up with AC Immune for Alzheimer’s drugEli Lilly has signed a licence and collaboration agreement with Swiss biotech AC Immune for the research and development of tau aggregation inhibitor small molecules to treat neurodegenerative disorde2018/12/14
-
NIH to support HIV care and prevention research in the USThe National Institute of Allergy and Infectious Diseases (NIAID), a National Institutes of Health (NIH) division, has announced plans to fund human immunodeficiency virus (HIV) care and prevention re2018/12/14
-
Pfizer still unable to get on top of problems at Hospira injectables plantSince Pfizer’s Kansas plant received an FDA warning letter last year, the company has insisted it is making good progress on turning things around at the essential but troubled injectables facility. B2018/12/13
-
As competition heats up, U.S. prices for Remicade and biosims slip: analystAs Johnson & Johnson vies with biosimilars to its big-selling Remicade, prices across the category are gradually falling, an analyst says—and Pfizer's Inflectra has taken the biggest tumble. Th2018/12/13
-
Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejigMerck & Co. boasted some major success in the sales department this year, but the company’s commercial organization will still get a makeover for 2019. On Monday, the New Jersey company said Adam2018/12/12
-
China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safetyThe Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter for failing to uncover a suspected carcinogen in its APIs when a c2018/12/12
-
Acadia debuts first Nuplazid branded ads, aiming to spark talk of Parkinson's psychosisWith an FDA safety review in the rearview mirror, Acadia is back to business on Parkinson's psychosis therapyNuplazid—and launching its first branded ad campaign to boot. The Nuplazid TV ads made the2018/12/11
-
AstraZeneca kicks off second blood cancer launch, this time for orphan drug LumoxitiFor the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug. The company is in the process of rolling out Lumoxiti, a treatment for patients with the rare disease ha2018/12/11